Cizzle Biotechnology Limited completed the acquisition of Bould Opportunities PLC from Antos Glogowski and others in a reverse merger transaction.
The transaction is subject to placing agreement, admission, approval of offer by shareholders of Bould Opportunities PLC in a meeting scheduled on May 13, 2021. On April 23, 2021, the transaction was unanimously recommended by the Board of Directors of Bould Opportunities PLC. Tim Metcalfe and Florence Chandler of IFC Advisory Limited, John Depasquale and Alex Brearley Allenby Capital Limited acted as financial advisor, Goodman Derrick LLP acted as the legal advisor, PKF Littlejohn LLP acted as an accountant, Link Group acted as the registrar and Novum Securities Limited acted as the broker for Bould Opportunities PLC. Shakespeare Martineau LLP acted as the legal advisor for Cizzle Biotechnology Limited. Allenby Capital will get a corporate finance fee of £0.1 million payable on admission for acquisition, placing and admission.
Cizzle Biotechnology Limited completed the acquisition of Bould Opportunities PLC (AIM:BOU) from Antos Glogowski and others in a reverse merger transaction on May 13, 2021. Cizzle Biotechnology Limited's shares will begin trading under the ticker CIZ. Post-closing the name of Cizzle Biotechnology Technology Limited was changed to Cizzle Biotechnology Holdings Plc and the enlarged share capital will be admitted to the standard Listing segment of the official list and trading on the Main Market of the London Stock Exchange. On May 13, 2021, the transaction was approved by the shareholders of Bould Opportunities PLC.